Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection

Basit Öğe Kaydı
dc.authorid0000-0002-5299-9480en_US
dc.authorid0000-0002-8390-5109en_US
dc.contributor.authorDikici, Bünyamin
dc.contributor.authorBoşnak, Mehmet
dc.contributor.authorUçmak, Hasan
dc.contributor.authorDağlı, Abdullah
dc.contributor.authorEce, Aydın
dc.contributor.authorHaspolat, Yusuf Kenan
dc.date.accessioned2021-12-03T13:18:24Z
dc.date.available2021-12-03T13:18:24Z
dc.date.issued2003en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractSummary Aim: The aim of this study was to investigate the efficacy of specific hepatitis B virus (HBV) vaccination as active immunotherapy in treating chronic hepatitis B (CHB) infection during the immune-tolerant phase in children with normal aminotransferase levels and high viral load. Methods: Fifty-one immunotolerant patients were randomly and prospectively recruited into two groups. Group 1 included 23 patients that were vaccinated with three standard injections of the GenHevac B vaccine in the deltoid or quadricep muscle, initially, and at 30 days and 60 days, for specific immunization. Group 2 contained 28 patients who did not receive any medication or vaccination and were recruited as the control group. Post-vaccination evaluation was performed at 6 months from the first injection and at the end of the 12th month by serological and virological analyses. A response criterion to therapy was defined as loss of HBV-DNA in serum and hepatitis B early antigen (HBeAg) seroconversion (loss of HBeAg, development of antibody to HBeAg (anti-HBe)). Results: The mean alanine aminotransferase (ALT) value in group 1 at the beginning of the vaccination was 33.6 ± 8.1 IU/L; this changed to 31.7 ± 9.0 IU/L at 6 months after first injection and 29.2 ± 7.1 IU/L at the end of 12 months (P > 0.05). In this group, mean HBV-DNA load at the starting point of the vaccination was 3709 ± 1126 pg/mL; this value changed to 3569 ± 726 pg/mL at the sixth month and 3295 ± 832 pg/mL at the 12th month (P > 0.05). In group 2, the mean ALT values at the beginning of therapy, and at the 6th and 12th month were 32 ± 8 IU/L, 31.8 ± 8 IU/L, and 29.7 ± 7 IU/L, respectively (P > 0.05), and the mean viral load of HBV-DNA values were 3827 ± 1375 pg/mL, 3498 ± 886 pg/mL, and 3059 ± 731 pg/mL, respectively (P > 0.05). The load of HBV DNA of all patients in both groups was greater than 2000 pg/mL. There was no statistically significant difference in the mean ALT values and mean viral load of HBV DNA (P > 0.05) between group 1 and group 2 at the end of the 6th and 12th months. Except for one each patient in each group, hepatitis B surface antigen (HBsAg) and HBeAg clearance or antibody to HBsAg (anti-HBs) and anti-HBe seroconversion were not observed during the follow-up period (P > 0.05). Conclusion: In this study, comparison of vaccinated and unvaccinated groups of immunotolerant children with CHB infection showed no difference in the clearance of HBV DNA and seroconversion of HBeAg to anti-HBe. Different immunization protocols should be considered for future investigations in the immunotolerant phase of children with CHB infection.en_US
dc.identifier.citationDikici, B., Boşnak, M., Uçmak, H., Atlı, A., Ece, A., Haspolat, Y. K. ve diğerleri. (2003). Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. Journal of Gastroenterology and Hepatology, 18(2), 218-222.en_US
dc.identifier.doi10.1046/j.1440-1746.2003.02950.x
dc.identifier.endpage222en_US
dc.identifier.issn1440-1746
dc.identifier.issue2en_US
dc.identifier.pmid12542609
dc.identifier.scopus2-s2.0-0037300132
dc.identifier.scopusqualityQ1
dc.identifier.startpage218en_US
dc.identifier.urihttps://hdl.handle.net/11468/8358
dc.identifier.volume18en_US
dc.identifier.wosWOS:000180604400016
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorDikici, Bünyamin
dc.institutionauthorBoşnak, Mehmet
dc.institutionauthorUçmak, Hasan
dc.institutionauthorDağlı, Abdullah
dc.institutionauthorEce, Aydın
dc.institutionauthorHaspolat, Yusuf Kenan
dc.language.isoenen_US
dc.publisherJournal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australiaen_US
dc.relation.ispartofJournal of Gastroenterology and Hepatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChildrenen_US
dc.subjectChronic hepatitis Ben_US
dc.subjectImmunotolerant perioden_US
dc.subjectTherapyen_US
dc.subjectVaccineen_US
dc.titleFailure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infectionen_US
dc.titleFailure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Failure of therapeutic vaccination using hepatitis B surface antigen.pdf
Boyut:
84 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu